I agree that uplifting will push CYDY to new levels. I was in a biotech a few years ago that did a reverse split and uplisted prior to good, but preliminary data. The stock went up 220% after uplisting, and had already doubled in the months before that as excitement for the prelim data grew. The company had many large investment firms buy in after the uplisting, which helped. Leronlimab is much farther than that drug and has much more promise, so I think an increase of 200-300% isn’t unreasonable.
Patience is the key with CYDY as approval for combo is nearly 99.9% guaranteed and mono may have a similar chance. The game we play now is waiting for the BLA to be submitted and approved and the dilution in between there.